Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

Stopped early · Not applicable · Has a placebo group

Conditions studied: Chronic Kidney Disease

In brief

The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.

Key facts

Study ID

NCT00586261

Run by

Mayo Clinic

People needed

36

Starts

2006-03-01

Expected to finish

2009-07-01

Last updated by the study team

2013-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age over 18 years.
• Creatinine clearance ≤ 60 ml/min by the Cockcroft-Gault equation
• Patients not anticipated to go on dialysis or have renal transplantation in the next 6 months
• Ability to provide informed consent
• Life expectancy greater than 12 months

You may not qualify if…

• Diabetes mellitus or a fasting blood glucose ≥ 110 mg/dL
• Acute renal failure
• Class 3 or 4 heart failure
• Liver failure, ascites, or an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) two times the upper limit of normal
• Hemoglobin less than 9 mg/dL
• Multiple myeloma
• Premenopausal women not using at least 1 form of birth control
• Pregnant or nursing women
• Prisoners
• Known allergy to pioglitazone

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.